Pre-Test Utility of Clinical Pathways for Multiple Myeloma: Navigating Updates in Guidelines and Care Pre-Test According to current recommendations from the International Myeloma Working Group, the preferred option of treatment for the first MM relapse not refractory to lenalidomide is: Daratumumab, lenalidomide, dexamethasone Elotuzumab, pomalidomide, dexamethasone Isatuximab, carfilzomib, dexamethasone Isatuximab, pomalidomide, dexamethasone Unsure This bispecific antibody targets the GPRC5D surface antigen and has demonstrated efficacy in overall response for patients with relapsed or refractory MM: Alnuctamab Blinatumomab Cevostamab Talquetamab Unsure Please rate your understanding of the role of clinical pathways in improving outcomes and managing patient costs associated with MM treatment. Excellent Very good Good Fair Poor How confident are you in your ability to integrate novel agents and formulations into clinical pathways for MM? Very confident Confident Somewhat confident Not very confident Not at all confident
